Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.40 |
| ▸ | IDH1 | O75874 | 4/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120834 | 1.00 | S1PR1 (0.41) | S1PR1ALOX5P2RX3IDH1PTPN22 | |
| SCHEMBL4133591 | 0.91 | ALOX5 (0.50) | ALOX5HDAC4HDAC8 | |
| SCHEMBL4133593 | 0.91 | ALOX5 (0.50) | ALOX5HDAC4HDAC8 | |
| SCHEMBL4134117 | 0.88 | PTPN22 (0.51) | ALOX5PTPN22HDAC4PPARGHDAC8 | |
| SCHEMBL4134114 | 0.88 | PTPN22 (0.51) | ALOX5PTPN22HDAC4PPARGHDAC8 | |
| SCHEMBL4140263 | 0.86 | ALOX5 (0.47) | ALOX5 | |
| SCHEMBL4140267 | 0.86 | ALOX5 (0.47) | ALOX5 | |
| SCHEMBL4137400 | 0.85 | ALOX5 (0.38) | ALOX5PTPN22 | |
| SCHEMBL4137396 | 0.85 | ALOX5 (0.38) | ALOX5PTPN22 | |
| SCHEMBL4128924 | 0.82 | S1PR1 (0.43) | S1PR1P2RX3IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| EP-1934192-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2008-06-25 | — | — | EP | claimed |
| WO-2007032028-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-03-22 | — | — | WO | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | S1PR1 3366/4885ALOX5 3505/4885P2RX3 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.